Monoclonal Antibodies (mAbs) for Oncology Global Report 2026: A $228 Billion Market by 2030, Driven by Technological Advances, New Product Launches, Label Expansions, Increasing Prevalence
Dublin, March 02, 2026 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global market for monoclonal antibodies in oncology is expected to grow from $129.3 billion in 2025 and is projected to reach $228 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12% during the forecast period of 2025 to 2030.
The report provides detailed information on monoclonal antibodies in oncology. This report analyzes the market trends and includes global revenue ($ million) for the base year 2024, estimated data for 2025, and forecast data from 2025 through 2030. The report highlights the current and future market potential of monoclonal antibodies in oncology and provides a detailed analysis of the competitive environment. It includes regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key companies.
Monoclonal antibodies (mAbs) are a significant class of treatments in oncology, with extensive research establishing their role in fighting various cancers. These drugs are targeted therapies created using modern scientific techniques, including genetic engineering and recombinant DNA technology. Unlike conventional treatments, such as chemotherapy, mAbs offer a more effective and targeted approach. They are predominantly produced in mammalian cell lines, such as Chinese hamster ovary (CHO) cells, and have been utilized in oncology since the discovery of the first therapeutic mAb in 1997.
The market for mAbs in oncology is rapidly evolving due to technological advances, new product launches, label expansions, increasing cancer prevalence and rising patient awareness. Market pressures include R&D spending, increasing competition, patent expiries and the introduction of new technologies. Monoclonal antibodies are used in advanced formats, such as antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), targeting pro-tumorigenic compounds in the microenvironment and Immune Checkpoint Inhibitors (ICIs). Keytruda, the market's highest-selling drug, is a prime example of these innovations.
Report Scope
The market scope in this report is segmented by type, cancer type and region. By type, the market is segmented into humanized, human and chimeric. The cancer type segment is characterized into lung cancer, breast cancer, colorectal cancer, lymphoma, leukemia, melanoma, multiple myeloma and other cancers.
The region covered in this study includes North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America. The regional segment provides a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India.
Company Profiles
Key Attributes:
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies, Clinical Trial Analysis and Patent Analysis
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in the Global Market for Monoclonal Antibodies in Oncology: An ESG Perspective
Chapter 9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/aks6zk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment